RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit
December 03, 2024 07:35 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
December 02, 2024 18:22 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
November 29, 2024 20:40 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million
November 28, 2024 23:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Private Placement Offering
November 27, 2024 21:33 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
November 25, 2024 07:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
November 20, 2024 16:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain
October 25, 2024 07:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform
October 23, 2024 07:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
September 17, 2024 07:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel...